Trillium Therapeutics Inc. (NASDAQ:TRIL) is among the top stocks that may remain in focus today as the company shares are trading 4.68% or 0.018 points lower from last closing price of $0.385, reaching $0.367 at last check. Any clue why there is so much of action in the TRIL stock? The share price has dropped in 3 of the last 5 days and is down -43.76% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -45,641 shares, and in total 349959 shares valued at $128435 were seen changing hands compared with 395600 shares valued at $152306 recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the TRIL stock is near its bottom.
Trillium Therapeutics Inc. (TRIL) shares have notched a 3-month decline of about -43.76%, but has still tumbled -77.48% year to date. By comparison, the stock sank -93.53% over the past 12 months, while it slipped -33.98% over the 1 month. The company’s market cap is around $5.66M, with its short interest ratio standing at 1.72%.
In the current trading session for TRIL, the stock witnessed two major price actions, it rose to a high of $0.39 and was down as much as $0.367 at one point. The high recorded is very low when compared to their 52-week high which is $0.35. The 52-week high is now at -94.73 distance from current price. Their recent low of $7 represents a 6.28% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for TRIL is $11.02, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
TRIL‘s last price was down -83.14% as compared to the average trading price of 50 days recorded at $2.18 while enlarging the period to 200 trading days, the average closing price was $0.54. At present, there are 14.69 million in the total number of common shares owned by the public and among those shares have been available to trade. The percentage of shares being held by the company management was 0.26% while institutions stake was 40.67%. The company has generated negative returns on equity over the last 12 months (0%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the TRIL stock, there is another set of technicals that should be looked into and considered. Its -14.59% decline from moving average of $0.43 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Trillium Therapeutics Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $4 on shares of Trillium Therapeutics Inc. (NASDAQ:TRIL), which corresponds to 981.08% upside potential than its current market price of $0.367 and implies potential despite the recent drop in the price. However, their current target price has fallen from $4 a month ago and is down handily from the consensus target of $5.5 a quarter ago.
Let’s briefly check the hedge fund interest towards TRIL stock. Marshall Wace LLP added position in the company after it grew 50% or 73,521 shares of its common stock. The hedge fund now owns 110,282 shares worth $40,473, SEC documents show. Morgan Stanley shored up assets in the stock as 619387 shares have been purchased, increasing its stake by 24.3% to 769,898 shares which are currently valued at $282,553. In addition, Oxford Asset Management LLP recently reported that it now owns 93,589 shares making a total of $34,347 based on the recent price. This refelects a change of 28.1% in their ownership.